Bioxcel Therapeutics: Navigating Financial Pressures and Clinical Trials A Hold Rating AnalysisTipRanks Financial Blog • 24 days ago
Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on BTAI stock, giving a Hold rating on March 13. Graig Suvannavejh...
Share to Feed
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the Company ) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop...
Bioxcel Therapeutics (BTAI) has disclosed a new risk, in the Accounting & Financial Operations category. Bioxcel Therapeutics' projections of marke...
HC Wainwright reissued their buy rating on shares of BioXcel Therapeutics (NASDAQ:BTAI Free Report) in a research note published on Monday morning, Benzinga reports. HC Wainwright currently...
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics (BTAI Research Report) today and set a price target of $11...
Newly granted patent aligns with Company's focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501NEW HAVEN, Conn., March 15, 2024 (GLOBE NEWSWIRE...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Investors eyeing a purchase of BioXcel Therapeutics Inc (BTAI) stock, but cautious about paying the going market price of 2.78/share, might benefit from considering selling puts among the...
Related Stocks: NAS:BTAI...
Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Recently completed meetings with U.S. Food and Drug Administration for TRANQUILITY and SERENITY...